Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.

ABSTRACT:

Background

Patients with primary immunodeficiency disease (PIDD) and antibody deficiency require lifelong immunoglobulin replacement therapy. While both subcutaneous immunoglobulin (SCIG) and intravenous immunoglobulin (IVIG) replacement therapy are effective in preventing infection, patients with PIDD still experience worse health-related quality of life (hrQOL) outcomes.

Objective

Assess differences in hrQOL for PIDD patients receiving home SCIG versus IVIG.

Methods

SF-36 surveys were administered by a specialty pharmacy to 630 PIDD patients receiving home SCIG and IVIG at baseline and then every 3 months between 2014 and 2016. Results were analyzed using two-sample t tests and linear mixed effects model. Analysis was repeated for different age categories and trende

SUBMITTER: Anterasian C 

PROVIDER: S-EPMC6863943 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature